[Comparison of different antifungal treatment regimens for experimental Candida endophthalmitis in rabbit models].
The aim of this study was to evaluate the treatment options of experimental in-vivo Candida endophthalmitis. For inoculation, a 0.1 ml of suspension of Candida albicans was injected into the vitreous of the right eye of each New Zealand rabbit. On the 15th day, the clinical evaluation for the resultant endophthalmitis was noted, and vitreous samples were obtained. On the 21st day, culture positive eyes were divided into four groups in terms of treatment modalities. Group 1 (n = 7) received intravitreal amphotericin B injection, group 2 (n = 8) received both intravitreal dexamethasone and amphotericin B injections, group 3 (n = 8) underwent pars plana vitrectomy (PPV) and amphotericin B injection, and group 4 (n = 8) underwent PPV and both amphotericin B and silicone oil injections. The vitreous samples obtained from right eyes of the rabbits on the 15th day, were all culture positive for Candida albicans. On the 35th day, the least colony counts (colony forming unit) were present in eyes that received only intravitreal amphotericin B injection in group 1, followed by group 4 that underwent PPV and both amphotericin B and silicone oil injections. In Candida endophthalmitis, intravitreal injection of amphotericin B without steroid appears to be the primary choice of therapy. In cases who fail to respond to this regimen alone, PPV in combination with silicone oil injection may be considered. Benefit-risk ratio should be cautiously interpreted for application of intravitreal steroid injection.
Koçak
Nilüfer
N
Dokuz Eylül Universitesi Tip Fakültesi, Göz Hastaliklari Anabilim Dali, Izmir. nkocak@yahoo.com
Kaynak
Süleyman
S
Kirdar
Sevin
S
Irmak
Ozgür
O
Bahar
I Hakki
IH
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D056965:Injections, Intraocular; D008297:Male; D011817:Rabbits; D018570:Risk Assessment; D012827:Silicone Oils / Q000008:administration & dosage; D014821:Vitrectomy; D014822:Vitreous Body / Q000382:microbiology
D000935:Antifungal Agents; D005938:Glucocorticoids; D012827:Silicone Oils; D003907:Dexamethasone; D000666:Amphotericin B